Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11802152 Methods of treating FGF21-associated disorders

Patent 11802152 was granted and assigned to Novartis on October, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Brian Boettcher

Fangmin Xu

Regis Cebe

David Langdon Yowe

Guochun Li

Shari Lynn Caplan

John A. Taraszka

Date of Patent

October 31, 2023

Patent Application Number

17539335

Date Filed

December 1, 2021

Patent Citations

US Patent 9085626 FGFR1 agonists and methods of use

US Patent 8372952 Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho

US Patent 8697369 Method for screening a test substance for activating a receptor associated with FGF 21 activity

US Patent 8722622 FGF21 conjugates and anti-diabetic uses thereof

US Patent 9006400 Fibroblast growth factor-21-Fc fusion proteins

US Patent 9284378 Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof

Patent Primary Examiner

Marianne P Allen

Patent abstract

The present invention relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human β-klotho, and pharmaceutical compositions and methods of treatment comprising the same.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11802152 Methods of treating FGF21-associated disorders

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool